Table 3 Treatment in relation to chemotherapy schedule
Treatment characteristic | 1w-CDDP (N.114) | 3w-CDDP (N.52) | p | Entire series (%) |
|---|---|---|---|---|
Cumulative CDDP/m2 dose | 0.000 | |||
≤ 200 mg/m2 | 82 (71.9%) | 14 (26.9%) | 96 (57.8%) | |
200–250 mg/m2 | 29 (25.4%) | 12 (23.1%) | 41 (24.7%) | |
> 250 mg/m2 | 3 (2.6%) | 26 (50%) | 29 (17.5%) | |
Median CDDP/m2 | 175.9 mg/m2 | 248.1 mg/m2 | 0.026 | |
CDDP interruption | ||||
Yes | 64 (56.1%) | 18 (34.6%) | 0.012 | 82 (49.4%) |
No | 50 (43.9%) | 34 (65.4%) | 84 (50.6%) | |
RTT dose | 0.000 | |||
69 Gy | 10 (8.8%) | 0 | 10 (6%) | |
> 69 Gy and < 70 Gy | 47 (41.2%) | 0 | 47 (28%) | |
70 Gy | 57 (50%) | 52(100%) | 109 (66%) | |
RTT dose/fraction | 0.000 | |||
2.3 Gy/fr | 10 (8.8%) | 0 | 10 (6%) | |
2.1–2.2 Gy/fr | 47 (41.2%) | 0 | 47 (28%) | |
2 Gy/fr | 57 (50%) | 52(100%) | 109 (66%) | |
RTT technique | 0.000 | |||
3D | 3 (2.6%) | 4 (7.7%) | 7 (4.2%) | |
IMRT (VMAT) | 53 (46.5%) | 48 (92.3%) | 101 (60.8%) | |
Helical IMRT | 58 (50.9%) | 0 (0%) | 58 (34.9%) | |